AUTHOR INDEX TO VOLUME 1

Ashby, J., 44

Baine, M. J., 9, 167
Barash, C. I., 277
Bass, R., 183
Branin, M.-J., 197
Brunelle, R. L., 95
Burlington, D. B., 143

Cato, A., 1, 79
Clive, D., 11, 179
Cocchetto, D. M., 87, 153, 185, 313
Cook, L., 9

DeMets, D., 121
Dren, A. T., 79

Enas, G. G., 95
Eto, C. Y., 197

Faich, G. A., 75
Flamm, W. G., 180

Glocklin, V., 182
Gorodetsky, C. W., 79
Green, S., 180
Gubish, E. R., 143

Hadley, P. A., 53
Hizer, R. E., 53
Hull, P., 317

Ishidate, M., 50

Johnson, J. R., 187

Kaitlin, K. I., 263
Kammer, J. W., 307

Lasagna, L., 277
Lawson, D. H., 75
Lister, W. C., 53
Lue, J. C., 197

Madle, S., 183
McCarthy, C. R., 131
Michie, D. D., 205
Müller, L., 183

Nahata, M. L., 307
Nardi, R. V., 153, 301
Newberne, P. M., 42
Niedel, J., 83
Novack, G. D., 197

Pettinga, C. W., 53

Rader, M., 53
Roe, F. C., 179
Ruoff, G. E., 293

Schoenfeld, L. V., 205
Schwaig, G. L., 205
Simpson, P. J., 95
Stang, P., 221
Storer, B., 121

Talbott, M. W., 53
Thompson, W. L., 53, 95
Tilson, H. H., 75
Trimble, A. G., 263

Vlasses, P. H., 315
Von Wittenau, S., 47

Walker, A., 75
Werner, K., 187

Journal of Clinical Research and Drug Development 1, 321 (1987)

© 1987 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
52 Vanderbilt Avenue, New York, NY 10017

0889-5813/87/$3.50

SUBJECT INDEX TO VOLUME 1

ABNORMAL RESULTS
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

ADVERSE DRUG EVENTS
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

ADVERSE DRUG REACTIONS
Clinical Trials Are Not Enough: Drug Development and Pharmacoepidemiology, 75
Serum Concentrations and Adverse Effects of Vancomycin in Pediatric Patients, 307

AGING
Survey of Concurrent Diseases and Pharmacotherapeutics in Impotent Elderly Men, 205

ANTIHYPERTENSIVE THERAPY
Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs, 293
Commentary on "Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs," by Dr. Gary E. Ruoff, 301

BENDECTIN
The Bendectin Saga: "Voluntary" Discontinuation, 277

BETA-ADRENOCEPTOR ANTAGONISTS
A Postmarketing Evaluation of Levobunolol, a Topical Antiglaucoma Drug, 197

BIOLOGICAL PRODUCT
Review of Investigational Biological Products by the United States Food and Drug Administration, 143

BLOOD TESTS
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

CARCINOGENITY
Genetic Toxicology: From Theory to Practice, 11

CARDIAC MEDICATION
Survey of Concurrent Diseases and Pharmacotherapeutics in Impotent Elderly Men, 205

CLINICAL DRUG DEVELOPMENT
Achievement of Continuity and Research Equity in Clinical Drug Development, 153

CLINICAL RESEARCH ASSOCIATES
Centralization Versus Decentralization Management Specific to Clinical Research Associates in the Pharmaceutical Industry, 167

CLINICAL TRIALS
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95
Current Phase I/II Designs: Are They Adequate?, 121
Accuracy of Data Collection in a Clinical Trial with Guidelines for Case Report Auditing, 187

DATA LINKAGE
Clinical Trials Are Not Enough: Drug Development and Pharmacoepidemiology, 75

DRUG DEVELOPMENT
Genetic Toxicology: From Theory to Practice, 11
Clinical Trials Are Not Enough: Drug Development and Pharmacoepidemiology, 75

DRUG EPIDEMIOLOGY
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

DRUG EVENTS
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

DRUG PRICE COMPETITION
Implementation of the Drug Price Competition and Patent Term Restoration Act of 1984: A Progress Report, 263

DRUG REGULATION
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

Journal of Clinical Research and Drug Development 1, 323–325 (1987)

© 1987 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
52 Vanderbilt Avenue, New York, NY 10017

0889-5813/87/$3.50

DRUG TOXICITY
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

EFFICACY
Review of Investigational Biological Products by the United States Food and Drug Administration, 143
Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs, 293

EVENT INCIDENCE
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

FDA
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53
The Bendectin Saga: "Voluntary" Discontinuation, 277

FEDERAL PROTECTIONS
Federal Protections for Human Research Subjects: Historial Perspective, 131

GENERIC DRUGS
Implementation of the Drug Price Competition and Patent Term Restoration Act of 1984: A Progress Report, 263

GENETIC TOXICOLOGY
Genetic Toxicology: From Theory to Practice, 11
Commentary on "Genetic Toxicology: From Theory to Practice," by D. Clive, 42

GERM CELL MUTAGENESIS
Genetic Toxicology: From Theory to Practice, 11

HUMAN RESEARCH SUBJECTS
Federal Protections for Human Research Subjects: Historical Perspective, 131

IMPOTENCE
Survey of Concurrent Diseases and Pharmacotherapeutics in Impotent Elderly Men, 205

INVESTIGATIONAL NEW DRUGS
Review of Investigational Biological Products by the United States Food and Drug Administration, 143

LABORATORY TESTS
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

LEVOBUNOLOL
A Postmarketing Evaluation of Levobunolol, a Topical Antiglaucoma Drug, 197

LIVER FUNCTION TESTS
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

MANAGEMENT TECHNIQUES FOR CRAs
Centralization Versus Decentralization Management Specific to Clinical Research Associates in the Pharmaceutical Industry, 167

MONITORING CLINICAL TRIALS
Accuracy of Data Collection in a Clinical Trial with Guidelines for Case Report Auditing, 187

MUTAGENS
Genetic Toxicology: From Theory to Practice, 11

NONINVASIVE TESTING
Survey of Concurrent Diseases and Pharmacotherapeutics in Impotent Elderly Men, 205

NORMAL VALUES
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

NORMOTENSION
Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs, 293

OPEN-ANGLE GLAUCOMA
A Postmarketing Evaluation of Levobunolol, a Topical Antiglaucoma Drug, 197

OUTLYING VALUES
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

PATENT
Implementation of the Drug Price Competition and Patent Term Restoration Act of 1984: A Progress Report, 263

PEDIATRIC PATIENTS
Serum Concentrations and Adverse Effects of Vancomycin in Pediatric Patients, 307

PERCENTILE LIMITS
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

PHARMACEUTICALS
Genetic Toxicology: From Theory to Practice, 11

PHARMACOEPIDEMIOLOGY
Clinical Trials Are Not Enough: Drug Development and Pharmacoepidemiology, 75

PHASE I DESIGN
Current Phase I/II Designs: Are They Adequate?, 121

PHASE II DESIGN
Current Phase I/II Designs: Are They Adequate?, 121

POSTMARKETING SURVEILLANCE
Clinical Trials Are Not Enough: Drug Development and Pharmacoepidemiology, 75
A Postmarketing Evaluation of Levobunolol, a Topical Antiglaucoma Drug, 197

QUALITY CONTROL
Accuracy of Data Collection in a Clinical Trial with Guidelines for Case Report Auditing, 187

REFERENCE RANGES
Routine Laboratory Tests in Clinical Trials: Interpretation of Results, 95

REGULATORY AUTHORITIES
Adverse Drug Events: Global Collection, Analysis, and Reporting, 53

RESEARCH EQUITY
Achievement of Continuity and Research Equity in Clinical Drug Development, 153

SAFETY
Review of Investigational Biological Products by the United States Food and Drug Administration, 143

SAMPLING
Accuracy of Data Collection in a Clinical Trial with Guidelines for Case Report Auditing, 187

SHORT-TERM TESTS
Genetic Toxicology: From Theory to Practice, 11

TERAZOSIN
Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs, 293
Commentary on "Prolonged Normotension After Abrupt Withdrawal of Terazosin Treatment: Implications for Studies of the Efficacy of Antihypertensive Drugs," by Dr. Gary E. Ruoff, 301

VANCOMYCIN
Serum Concentrations and Adverse Effects of Vancomycin in Pediatric Patients, 307

WHITE BLOOD CELLS
The Case of the Disappearing White Blood Cells, 79